Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gallium-68 DOTATOC

Next Previous
Drug Profile

Gallium-68 DOTATOC

Alternative Names: 68Ga-DOTA(0)-phe(1)-tyr(3)-octreotide; 68Ga-DOTA-tyr3-Octreotide; 68Ga-DOTATOC; SomaKit-TOC

Latest Information Update: 30 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unknown
  • Developer Advanced Accelerator Applications; Icahn School of Medicine at Mount Sinai; Jiangsu Hengrui Medicine Co.; Turku University Hospital; University of Iowa
  • Class Organometallic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Neuroendocrine tumours
  • Phase III Myocarditis
  • Phase II/III Glioma

Most Recent Events

  • 17 Sep 2025 MedSIR plans a phase II THERANOVA trial for Solid tumours (Diagnosis) in unknown location (IV, injection) in April 2026 (NCT07178938)
  • 22 Feb 2024 Phase-III clinical trials in Neuroendocrine tumours (Diagnosis) in China (Parenteral) (NCT06091748)
  • 19 Oct 2023 Jiangsu HengRui Medicine plans a phase III trial for Neuroendocrine tumours (Diagnosis) in unknown location (NCT06091748)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top